Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Jul;80(10):1644–1647. doi: 10.1038/sj.bjc.6690575

Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation

U Menon 1, A Talaat 1, A R Jeyarajah 1, A N Rosenthal 1, N D MacDonald 1, S J Skates 2, K Sibley 1, D H Oram 1, I J Jacobs 1
PMCID: PMC2363093  PMID: 10408412

Abstract

We have previously shown that, in asymptomatic post-menopausal women, serum CA125 elevation is associated with a 36-fold increase in risk of ovarian cancer. This study was undertaken to assess the value of pelvic ultrasound for further stratification of ovarian cancer risk. Of 22 000 post-menopausal women, aged ≥ 45 participating in an Ovarian Cancer Screening Trial, 741 with a CA125 ≥ 30 U ml−1 underwent pelvic ultrasonography. Twenty index cancers (primary invasive epithelial carcinomas of the ovary and fallopian tube) were diagnosed amongst these 741 women during a median follow-up of 6.8 years. Ultrasound results separated the women with CA125 elevation into two groups. Those with normal ovarian morphology had a cumulative risk (CR) of index cancer of 0.15% (95% confidence interval (CI) 0.02–1.12) which is similar to that of the entire population of 22 000 women (0.22%, 95% CI 0.18–0.30). In contrast, women with abnormal ovarian morphology had a CR of 24% (15–37) and a significantly increased relative risk (RR) of 327 (156–683). Ultrasound can effectively separate post-menopausal women with raised CA125 levels into those with normal scan findings who are not at increased risk of index cancer and those with abnormal findings who are at substantially increased risk of index cancer. © 1999 Cancer Research Campaign

Keywords: ovarian cancer, risk, ultrasound, CA125, screening

Full Text

The Full Text of this article is available as a PDF (67.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Campbell S., Bhan V., Royston P., Whitehead M. I., Collins W. P. Transabdominal ultrasound screening for early ovarian cancer. BMJ. 1989 Dec 2;299(6712):1363–1367. doi: 10.1136/bmj.299.6712.1363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Gadducci A., Zola P., Landoni F., Maggino T., Sartori E., Bergamino T., Cristofani R. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol Oncol. 1995 Jul;58(1):42–47. doi: 10.1006/gyno.1995.1181. [DOI] [PubMed] [Google Scholar]
  3. Jacobs I. J., Skates S., Davies A. P., Woolas R. P., Jeyerajah A., Weidemann P., Sibley K., Oram D. H. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ. 1996 Nov 30;313(7069):1355–1358. doi: 10.1136/bmj.313.7069.1355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Jacobs I., Davies A. P., Bridges J., Stabile I., Fay T., Lower A., Grudzinskas J. G., Oram D. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ. 1993 Apr 17;306(6884):1030–1034. doi: 10.1136/bmj.306.6884.1030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Jacobs I., Oram D., Fairbanks J., Turner J., Frost C., Grudzinskas J. G. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol. 1990 Oct;97(10):922–929. doi: 10.1111/j.1471-0528.1990.tb02448.x. [DOI] [PubMed] [Google Scholar]
  6. Jacobs I., Stabile I., Bridges J., Kemsley P., Reynolds C., Grudzinskas J., Oram D. Multimodal approach to screening for ovarian cancer. Lancet. 1988 Feb 6;1(8580):268–271. doi: 10.1016/s0140-6736(88)90351-0. [DOI] [PubMed] [Google Scholar]
  7. Nagele F., Petru E., Medl M., Kainz C., Graf A. H., Sevelda P. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol. 1995 Aug;86(2):259–264. doi: 10.1016/0029-7844(95)00126-c. [DOI] [PubMed] [Google Scholar]
  8. Rustin G. J., Nelstrop A. E., McClean P., Brady M. F., McGuire W. P., Hoskins W. J., Mitchell H., Lambert H. E. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol. 1996 May;14(5):1545–1551. doi: 10.1200/JCO.1996.14.5.1545. [DOI] [PubMed] [Google Scholar]
  9. Rustin G. J., Nelstrop A. E., Tuxen M. K., Lambert H. E. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol. 1996 Apr;7(4):361–364. doi: 10.1093/oxfordjournals.annonc.a010602. [DOI] [PubMed] [Google Scholar]
  10. Tingulstad S., Hagen B., Skjeldestad F. E., Onsrud M., Kiserud T., Halvorsen T., Nustad K. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br J Obstet Gynaecol. 1996 Aug;103(8):826–831. doi: 10.1111/j.1471-0528.1996.tb09882.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES